Atrial Natriuretic Peptide (ANP), rat: Mechanisms & Research Utility

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino acid peptide hormone produced by atrial myocytes and released in response to atrial stretch and neurohormonal stimuli (APExBIO datasheet). ANP acts as a potent vasodilator and regulator of sodium and water excretion, directly impacting blood pressure homeostasis. The APExBIO A1009 product is supplied as a high-purity (>95.9% by HPLC/MS) solid and is widely adopted in cardiovascular, renal, and adipose tissue metabolism studies (reference). Its efficacy and solubility profiles enable reproducible experimental outcomes, with prompt use in solution recommended for optimal results. ANP's mechanistic functions extend to neuroimmune and metabolic cross-talk, supporting translational research in disease models (DOI).

Biological Rationale

Atrial Natriuretic Peptide (ANP) is synthesized, stored, and secreted by cardiac atrial myocytes. Its release is triggered by increased atrial wall stretch, angiotensin II, endothelin, and sympathetic nervous system activation. ANP exerts systemic effects by binding to natriuretic peptide receptors (NPRs), initiating vasodilation and promoting renal sodium excretion (natriuresis). This hormone is essential for regulating extracellular fluid volume, arterial blood pressure, and electrolyte balance. In rats, the ANP peptide sequence is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, with a molecular formula of C49H84N20O15S and a molecular weight of 1225.38 (APExBIO). Disruption in ANP signaling is implicated in hypertension, heart failure, and metabolic syndrome (see also).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP binds preferentially to the natriuretic peptide receptor-A (NPR-A/GC-A), activating guanylyl cyclase and increasing intracellular cyclic GMP (cGMP) concentrations. Elevated cGMP mediates smooth muscle relaxation for vasodilation and inhibits sodium reabsorption in the renal collecting ducts, enhancing natriuresis and diuresis. ANP also inhibits renin, aldosterone, and vasopressin release, contributing to its antihypertensive and diuretic actions. In adipose tissue, ANP stimulates lipolysis and regulates adiponectin production, linking cardiovascular and metabolic pathways (Zhang et al., 2022). These mechanisms make the Atrial Natriuretic Peptide (ANP), rat reagent a critical tool for dissecting blood pressure homeostasis and natriuresis mechanisms in experimental models.

Evidence & Benchmarks

• ANP induces rapid and reversible vasodilation in isolated rat aortic rings via NPR-A receptor activation (see Table 2, DOI).
• Administration of 10 μg/kg/day ANP in Sprague Dawley rats significantly increased urinary sodium excretion over 24 hours compared to controls (DOI).
• APExBIO’s ANP (A1009) achieves ≥95.92% purity (HPLC/MS), supporting reproducible outcomes in cardiovascular and renal research workflows (internal link).
• ANP is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water at room temperature, allowing flexible assay design (APExBIO).
• ANP suppresses aldosterone secretion from the adrenal cortex, reducing sodium retention and plasma volume under hypertensive conditions (DOI).

This article extends the workflow guidance of 'Atrial Natriuretic Peptide (ANP), rat: Workflow Solutions...' by integrating direct mechanism-of-action evidence and recent benchmarks in metabolic and neuroimmune research.

Applications, Limits & Misconceptions

ANP is widely used in cardiovascular, renal, and metabolic disease models, including hypertension, heart failure, and obesity research. It enables controlled studies of blood pressure homeostasis, natriuresis, and adipose tissue metabolism regulation. The high purity and batch-to-batch consistency of the APExBIO product minimize confounders in sensitive cell and animal assays (reference). ANP also facilitates investigation of neurocardiometabolic crosstalk, supporting research into neuroinflammation and cognitive decline via modulation of adiponectin and TLR4/MyD88/NF-κB pathways (DOI).

Common Pitfalls or Misconceptions

• ANP is ineffective in ethanol-based solutions due to insolubility; use DMSO or water for dissolving the peptide (APExBIO).
• Long-term storage of ANP solutions, especially at room temperature, leads to rapid degradation—prepare fresh aliquots for each use.
• ANP does not replicate chronic heart failure pathophysiology in acute models; interpret results accordingly.
• Overreliance on single-dose studies may overlook dose-dependent or context-specific effects.
• ANP's actions in non-rodent species may differ; product validation is rat-specific.

This review updates the mechanistic synthesis in 'Mechanistic Horizons and Strategic Pathways...' by detailing recent experimental evidence and clarifying boundaries of effective use.

Workflow Integration & Parameters

The APExBIO Atrial Natriuretic Peptide (ANP), rat (SKU A1009), is provided as a lyophilized solid, stored at -20°C, and reconstituted in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL). Ethanol should be avoided due to insolubility. For cell and animal studies, prepare fresh working solutions and use promptly to prevent peptide degradation. High purity (>95.92% by HPLC and MS) ensures experimental reliability. The product is validated for cardiovascular and renal physiology research, blood pressure homeostasis assays, natriuresis mechanism studies, and adipose tissue metabolism investigations. For detailed troubleshooting and advanced workflows, see 'Atrial Natriuretic Peptide: Applied Workflows in Cardiova...', which this article expands by providing direct solubility and purity benchmarks.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat, is a cornerstone reagent for dissecting cardiovascular, renal, and metabolic pathways in preclinical research. The high-purity APExBIO product (A1009) offers validated performance and reproducibility, supporting blood pressure homeostasis, natriuresis, and adipose tissue metabolism studies. Future research will continue to expand ANP applications in neuroimmune and translational disease models, leveraging robust benchmarks and workflow integration for impactful outcomes. For product specifications and ordering, refer to the APExBIO product page.